
REVIEW ARTICLE

Protection of the Neonate by the Innate Immune System of Developing Gut and of Human Milk

DAVID S. NEWBURG, AND W. ALLAN WALKER

Glycobiology and Mucosal Immunology Laboratories, Pediatric Gastroenterology and Nutrition Unit, MassGeneral Hospital for Children and Harvard Medical School, Boston, Massachusetts

ABSTRACT: The neonatal adaptive immune system, relatively naïve to foreign antigens, requires synergy with the innate immune system to protect the intestine. Goblet cells provide mucins, Paneth cells produce antimicrobial peptides, and dendritic cells (DCs) present luminal antigens. Intracellular signaling by Toll-like receptors (TLRs) elicits chemokines and cytokines that modulate inflammation. Enteric neurons and lymphocytes provide paracrine and endocrine signaling. However, full protection requires human milk. Breast-feeding reduces enteric infection and may reduce chronic disease in later life. Although human milk contains significant secretory immunoglobulin A (sIgA), most of its protective factors are constitutively expressed. Multifunctional milk components are nutrients whose partial digestion products inhibit pathogens. Cytokines, cytokine receptors, TLR agonists and antagonists, hormones, anti-inflammatory agents, and nucleotides in milk modulate inflammation. Human milk is rich in glycans (complex carbohydrates): As prebiotics, indigestible glycans stimulate colonization by probiotic organisms, modulating mucosal immunity and protecting against pathogens. Through structural homology to intestinal cell surface receptors, glycans inhibit pathogen binding, the essential first step of pathogenesis. Bioactive milk components comprise an innate immune system of human milk whereby the mother protects her nursing infant. Interactions between human milk glycans, intestinal microflora, and intestinal mucosa surface glycans underlie ontogeny of innate mucosal immunity, pathobiology of enteric infection, and inflammatory bowel diseases. (*Pediatr Res* 61: 2–8, 2007)

At parturition, the mother-infant dyad switches from aseptic transfer of nutrients through the umbilicus to dependence on milk and the neonatal intestine to transfer nutrients and protect against enteric pathogens. A rich cornucopia of protective agents in the infant gut and in human milk may compensate for the naïve state of adaptive immunity in the neonate (1,2) and the immaturity of other gut systems. Many components contribute to a potent innate immune system of

neonatal gut and of human milk. The adaptive immune system is characterized by exquisite antigen specificity and delayed reaction that leads to memory, whereas the innate immune system, which is expressed constitutively, provides rapid or ongoing protection against broad groups of molecules without generating memory. The components of these innate immune systems of gut and milk are reviewed below to consider the degree to which they are complementary or synergistic. Their absence or malfunction may allow enteric disease, including inflammatory bowel diseases.

INTESTINAL MUCOSA

The intestinal mucosa is in intimate contact with microbiota, the symbiotic ecosystem of more than 450 species of mutualist and commensal microorganisms, often including opportunistic and obligate pathogens (3,4). The gut actively restrains these symbionts, especially the pathogens, constitutively with some elements of the innate immune system, reactively with other elements, and with some delay *via* the adaptive immune system. The most widely recognized element of the adaptive immune system is sIgA (5). The innate immune system is the sum of physical barriers (6), chemical barriers (including secretions), and reactive elements of local cells and cells recruited to a threatened site (7). The gut epithelium creates a tight barrier that separates luminal antigens and gut microbiota from invading the host (6) while activating underlying lymphoid elements (7). Activation of reactive cellular elements can also stimulate responses by the adaptive immune system. The epithelium is a first responder of the mucosal immune system (8).

The strong acid, proteases, and peptides secreted into stomachs of adults are major components of this barrier. In the infant, in whom these secretions are not as well developed (9), lingual and gastric lipases digest human milk triglyceride into free fatty acid (FFA) and monoglyceride (10), which, at concentrations found in stomachs of breast-fed infants, are known to be highly toxic to many human pathogens, especially enveloped viruses and some parasites (11).

Abbreviations: DCs, dendritic cells; NEC, necrotizing enterocolitis; PMNs, polymorphonuclear leukocytes; sIgA, secretory immunoglobulin A; TLR, Toll-like receptor

Received July 27, 2006; accepted September 14, 2006.
Correspondence: David S. Newburg, Ph.D., Program in Glycobiology, Pediatric Gastroenterology & Nutrition, MassGeneral Hospital for Children, 114 16th Street, Charlestown, MA 02129-4404; e-mail: dnewburg@partners.org
Funding for work on this review article was provided by grants P30-DK40561 (The Clinical Nutrition Research Center at Harvard), P01-HD13021 (Role of Human Milk in Infant Nutrition and Health), and R37-HD12437 (Effect of Colostrum on Gut Maturation and Host Defense).

DOI: 10.1203/01.pdr.0000250274.68571.18

A major physical barrier of the gut is the thick mucin-rich glycocalyx that lines the entire alimentary canal (12). In the intestine and colon, the epithelial monolayer is 93%–95% absorptive enterocytes (13), whose surface area is further increased by microvilli on apical surfaces. Because highly glycosylated proteins and lipids saturate microvilli, their electron micrographs resemble thick, dark, brushlike structures reminiscent of furry tails named glycocalyx (14). Within and extending beyond the glycocalyx is a thick layer of mucus secreted by goblet cells (3%–5% of mucosal epithelium) (15) that forms a physical barrier embedded with antimicrobial peptides (16) and Paneth cells (17,18). Where this mucus layer meets the luminal contents of the gut is a loosely formed biofilm of symbiotic microbiota. The composition and glycosylation of intestinal glycocalyx and mucins differ between neonates and adults. These differences may be a primary determinant of the distinct differences in microbial composition of the intestine of neonates and adults (19,20) and of their differing susceptibility to enteric pathogens.

Differentiated villus cells are replaced every 5 d in humans and every 3 d in rodents by proliferative cells descended from stem cells at the base of the crypts of Lieberkühn (13,15). These stem cells are protected by their recessed physical location (21,22) and by Paneth cells. As proliferative cells differentiate, one lineage is Paneth cells that migrate back toward the bottom of each crypt, where they secrete antimicrobial peptides, lysozyme, and other products that engender an aseptic sterile microdomain (16,18,23). Inhibiting colonization in the crypt minimizes microbial alteration, insult, or damage to stem cells, protecting their pristine nature for generating the lifelong stream of new naïve pluripotent cells required to maintain functional epithelium of the gut (24). These antibacterial inhibitors from the crypts may also become incorporated into the glycocalyx/mucin layer to help limit or localize colonization by all enteric symbionts: commensals, mutualists, and pathogens (2,4,19). Moreover, the production of antimicrobial peptides may be both temporally transient and spatially specific, which could limit microbial colonization to only the appropriate locations in the gut (25).

Interdigitating the villus structures are Peyer's patches, occasional dome-like follicle-associated epithelial structures located above aggregates of lymphocytes (26) containing uniquely differentiated microfold cells on the surface that monitor luminal antigens (27,28). Microbes and large molecules are sampled on the apical (luminal) side of microfold cells, and their antigens presented at the basal side to mucosal lymphoid elements (26,27), including macrophages and DCs. DCs, the primary antigen-presenting cells of the body, present the antigens locally to T lymphocytes or travel through the lymphatic system and present the antigens, principally in the mesenteric lymph node. Intestinal DCs are also found in the lamina propria, where their cytoplasmic extensions protrude across intact tight junction barriers through the villi into the lumen (8,29). They sample luminal contents and likewise present luminal antigens locally or in other areas of the lymphatic system, including mesentery, where they present processed antigens on appropriate MHC class molecules to generate specific primed T cells (8,27,28). This ultimately

results in production of sIgA in the gut, which can prevent luminal bacteria adherence to enterocyte surfaces (5). Although this system is underdeveloped in the newborn, very high concentrations of sIgA in colostrum and early milk may help to compensate.

The major resident phagocytic lymphoid cell in the gut is the macrophage (5,7,18,30,31), found in Peyer's patches and more diffusely in the lamina propria (28,30). The developing intestinal mucosa also acquires many mast cells that affect defense against intestinal parasites and enteric bacterial pathogens through tumor necrosis factor (TNF)- α release (32). Mast cells also mediate IgE-associated allergic responses (33). Epithelium produces various cytokines (34) and chemokines (35) that summon lymphocytes for mucosal immune response to infection or other breach of the epithelial barrier. Dispersed throughout the intestinal mucosa are endocrine cells and neurons; mucosal neuroendocrine secretions coordinate digestion, motility, gut regeneration and maturation, and immune functions both within the alimentary canal and with the other organ systems. The development and mode of distribution of these cells during intestinal ontogeny are not well understood.

Central to intestinal mucosal immunologic integrity are signals for sensing and reacting to both pathogenic and resident microbiota generated by the TLR family (36). TLR molecules (10 in humans, 11 in mice) bind epitopes characteristic of microbes, pattern recognition molecules (36,37). Each TLR initiates characteristic transcellular signals, activating nuclear transcription of genes whose products stimulate innate immune responses, including recruitment of cellular responders (38,39). The constant presence of microbiota requires selective attenuation of TLR signaling pathways in the intestinal epithelium to prevent chronic inflammation. In contrast, Paneth cells in crypts express TLR whose facile activation mediates release of potent antimicrobial agents (40). Overall, the intestinal mucosa must balance constant immunosurveillance, signaling to the periphery, and inflammatory homeostasis. The TLR expressed by intestinal epithelial cells (41) and intestinal macrophages (42) before birth are highly sensitive to stimulation, but after birth, TLR proteins, although still expressed, are much less active (43,44).

Immunologic monitoring of the gut lumen links local mucosal events to the peripheral immune system (8,27,28). Antigen-presenting cells, primarily DCs, continuously sample the luminal environment (29) and can mount a rapid cytokine response typical of innate immune responses and also activate the delayed antigen-specific lymphocyte response typical of the adaptive immune system (8,30). These two arms of the mucosal immune system initiate a self-limited inflammatory response in mature gut by recruiting activated neutrophils and monocytes into the lamina propria from blood vessels, normally mounting a localized immune response rather than a chronic systemic inflammatory response. This complex attenuation of the mucosal response in mature gut is incompletely developed in many premature infants (34,41). This could, in part, account for the excessive inflammatory response in premature infant gut in inflammatory bowel diseases such as necrotizing enterocolitis (NEC). Moreover, discrimination between pathogens and nonpathogenic symbionts involves im-

munomodulation that develops in the infant perinatally. Accordingly, for term infants, whose mucosal immune system is not fully mature, and especially for premature infants, whose mucosal immune system is immature, an exogenous source of supplementary immunosuppression, were it also to provide potent protection from pathogens, would be beneficial, if not essential. Human milk is the richest known source of such immunomodulation and protection.

HUMAN MILK

A relationship between breast-feeding and infant health had been recorded periodically for thousands of years across many disparate civilizations (45). In 1934, a report on 20,000 mother-infant dyads in the United States found that morbidity or mortality due to enteric disease was several times higher for nonbreast-fed infants than for breast-fed infants (46). With improved nutritional content of artificial infant formulas in the 1950s, better hygiene, greater weight gain in artificially fed infants, and the simultaneous dramatic reduction in infant mortality, many thought that this relationship was no longer relevant, and many medical settings actively discouraged breast-feeding. However, subsequent epidemiologic studies (47–49) in heavily populated areas of the world found that artificially fed infants were at three- to 10-fold higher risk of disease, especially enteric infections leading to diarrhea. When of careful design and adequate sample size, studies in developed nations also indicated a significantly lower frequency and/or severity of disease in breast-fed infants relative to those fed artificially (50,51). These differences suggest that human milk has protective and immunomodulatory activities that are lacking in even the best artificial formulas.

Furthermore, in developed countries, the increased number of premature infants in neonatal intensive care units has been accompanied by an epidemic of inflammatory bowel diseases, especially NEC. Ninety percent of NEC patients had been fed formula without human milk (52,53), and inclusion of human milk in the diet of the premature infant is associated with a lower risk of NEC. This is most often attributed to direct immunomodulation by milk, the prebiotic effect of its indigestible complex carbohydrates (glycans), the ability of glycans to inhibit colonization by pathogens, or combinations of these activities (2,31).

Recent reports associate artificial feeding of neonates with subsequent chronic diseases of later life, especially those with an autoimmune component (54). Notwithstanding unresolved questions regarding the mechanism underlying such associations and seemingly contradictory data, these associations could be attributed to three major phenomena. Neonatal mucosa allows potentially immunogenic macromolecules of the diet to cross the gut. Human milk accelerates maturation of the gut barrier function, but formula does not (55–57). Second, the neonate may be protected from pathogenic insults during this vulnerable period by bioactive components of human milk, including products of the adaptive immune system of the mother, primarily sIgA, and products of an innate immune system of human milk (58). Third, human milk




Figure 1. Enteromammary circulation allows the maternal mucosal immune system to protect the intestine of the infant *via* human milk. When an oral inoculum of a pathogen enters the maternal gut, it is sampled from the lumen by Peyer's patches, and its antigens are presented to underlying lymphatic cells. IgA production is induced at the basolateral side of the mammary cell, and the IgA traverses the mammary cell to enter the milk as sIgA. The sIgA enters the gut of breast-fed infants, where it protects the infant by binding to the pathogen. This is illustrated at the organ level in panel A (adapted from Kleinman RE and Walker WA 1979 *Digest Dis Sci* 24:876–882, © 1979 Springer Science+Business Media, Inc. 2006, with permission), and at the cellular level in panel B (adapted from Kraehenbuhl J-P et al. 1988 In: Hanson LA (ed) *Biology of Human Milk*. © 1988 Raven Press Ltd., with permission).

components could actively attenuate early inappropriate inflammatory reactions.

The first bioactive components recognized in human milk were antibodies. Transfer of immunity from mother to infant through milk was reported in 1892, and this was attributed to milk antibodies in 1903 (2,59). In 1905, intestinal microbiota of breast-fed infants was recognized as different from that of adults or of precociously weaned infants: Breast-fed infants had a predominance of lactobacilli, especially *Lactobacillus bifidus* (now *Bifidobacterium bifidum*), thought to acidify the gut and inhibit enteric pathogens from infecting breast-fed infants. Bioactive bifidus factors were identified as human milk glycans that stimulated colonization by *L. bifidus*. However, when 1 g/L sIgA was measured in human milk and up to 12 g/L in colostrum, concurrent with increased recognition that antibodies provide specific and robust protection, research on bioactive materials of human milk shifted to sIgA inhibition of infection by enteric pathogens (60). Enteromammary circulation of sIgA (Fig. 1 A) was elucidated: When the mother is exposed to a novel enteric pathogen, the pathogen is presented to the DC, the primary antigen-presenting cell, either indirectly by way of transcytosis through the M cell, or directly through endocytosis by the DC. T lymphocytes are activated, which can stimulate B lymphocytes either locally in the Peyer's patch or after migration to the mesenteric or other lymph node. Plasma cells ultimately produce IgA on the basolateral side of the mammary epithelial cell, the IgA attaches to the polyimmunoglobulin receptor, the complex traverses the mammary epithelial cell, and, with the exception of the secretory component that remains on the sIgA, the polyimmunoglobulin receptor is cleaved by protease on the apical side as dimeric sIgA is secreted from the apex of the acinar cell into the milk. When the infant consumes this milk, the sIgA is resistant to digestion, accumulates in the intestine, and binds to antigens on the pathogen to render it

less infective, thereby protecting the infant from the pathogen (Fig. 1 B). However, the many days that elapse between exposure of a mother (and infant) to a novel antigen and protection of the infant by sIgA in the milk make this mechanism of protection incomplete at best. Furthermore, genetically modified mice in which production of sIgA is knocked out are still protected against reinfection with *Salmonella typhimurium* or *Citrobacter rodentium*, indicating that mechanisms independent of sIgA protect the mucosa (61). Clearly, other mechanisms of protection contribute to the highly effective protection of breast-feeding, such as those afforded by milk components that we classify as the innate protective agents of human milk, including multifunctional agents, immunomodulators, and glycans.

Human milk components that serve as a major source of nutrients, but whose native form or partial digestion products also function to protect the infant, are multifunctional agents that we classify as part of an innate immune system of human milk. For example, lactoferrin, present at 1–3 g/L, is a major protein of human milk that chelates free iron, potentially assisting iron absorption by the infant. Unbound iron is an essential nutrient for many bacteria, and by making it unavailable, lactoferrin would also have a broad bacteriostatic effect. Lactoferrin also inhibits pathobiology of several bacteria (62–64), stimulates phagocytosis of pathogens by macrophages (65), and inhibits human immunodeficiency virus, cytomegalovirus, and herpesvirus (66,67). Partial digestion of lactoferrin produces lactoferricin B, a positively charged peptide loop of 18 amino acids with potent broad antibacterial activity for both Gram-positive and Gram-negative bacterial pathogens. Another protective milk protein is lysozyme, an enzyme that breaks β 1,4 bonds between *N*-acetylmuramic acid and *N*-acetyl glucosamine, a critical linkage in the peptidoglycans of bacterial cell walls. The amount of lysozyme in human milk varies, but is often approximately 100 μ g/L and is found in the feces of breast-fed infants (68), indicating that it survives intestinal digestion sufficiently to potentially break down the more vulnerable cell walls of Gram-negative bacteria. Haptocorrin, a human milk protein that chelates vitamin B₁₂, is resistant to digestion and inhibits enterotoxigenic *E. coli*.

The 4% fat (triglyceride) in human milk is a major source of calories for the infant, and a multifunctional component. As milk is consumed and mixes with lingual and gastric lipases, triglycerides are digested into FFAs and monoglycerides; at typical concentrations, these strongly inhibit enveloped viruses, some bacteria, and protozoans (11,69). The strongest inhibition is by monoglycerides, which act as detergents on pathogen membranes, and the fatty acids linoleic and lauric acid, which are especially high in human milk. Free oleic acid in conditions typical of the stomach of the breast-fed infant converts human milk α -lactalbumin into an alternate conformation named HAMLET (70), which is reported to induce apoptosis in tumors, leading to remission. The various multifunctional agents of human milk, working in synergy, provide a broad spectrum of inhibitors for immediate defense of breast-fed infants, providing one part of the proposed innate immune system of human milk.

HUMAN MILK COMPONENTS AND ONTOGENY OF INTESTINAL MUCOSAL IMMUNITY

The newborn infant gut, especially that of premature infants, is hypersensitive to proinflammatory stimuli and vulnerable to pathogens. Human milk contains immunomodulatory molecules that quench proinflammatory processes, large numbers of quiescent leukocytes of unknown function, and glycans, some of which promote colonization by symbionts and others that inhibit specific pathogens.

Many immunomodulatory molecules have been identified in human milk (71). Soluble TNF- α receptors and interleukin (IL)-1RA (receptor antagonist) of milk effectively suppress proinflammatory TNF- α and IL-1 activity, respectively (72,73), as does lactoferrin (74). Milk also contains anti-inflammatory cytokines IL-10 and transforming growth factor β (68), and many antioxidants, protease inhibitors, prostaglandins, and other agents that may contribute to immunosuppression. Human milk factors suppress induction of IL-8 expression (inflammatory response) in cultured intestinal epithelial cells; this suppression is greatest in immature cells, whose IL-8 response is more pronounced (71). These suppressive factors are at their highest concentrations in colostrum (75,76). Colostrum is consumed by neonates when priming and maturation of the mucosal immune system are greatest (77), and when the human gut can absorb macromolecules directly (24,55,56). An 80-kD protein from colostrum modulates the response by epithelial TLR-2, -4, and -5 to bacteria (78). Soluble CD14 mediates TLR-4 binding to lipopolysaccharide, the pattern recognition molecule of Gram-negative bacteria (79). Soluble CD14 concentrations are 20-fold higher in human milk than maternal serum (80); human milk-soluble CD14 may sensitize the innate mucosal immune system to Gram-negative bacteria, which include common pathogens of immature gut. Human milk also contains hormones, including epidermal growth factor, IGF, and leptin that can modulate the immune system of the intestinal mucosa *via* regulation of cytokine expression and other signaling pathways (81,82). Recently, adiponectin was found in human milk; adiponectin suppresses TNF- α production in intestinal epithelium and macrophages (83). Human milk suppresses inflammation in rat gut models (72). Thus, the immature human gut may be hyperresponsive to specific stimuli that could result in mucosal damage, but human milk has a cornucopia of factors that can modulate inflammatory responses.

The period when the immune system of the infant is naïve and priming and development are at their peak coincides with the earliest periods of lactation. Consistent with activation and stimulation of the adaptive immune system by breast-feeding, the thymus of breast-fed humans is significantly larger than the thymus of artificially fed infants (84). Human milk contains more than 10⁹ leukocytes per liter for the first several months of lactation, with the highest number in the initial days and weeks. By 6 mo, milk cells are 80% epithelial. Polymorphonuclear leukocytes (PMNs) are the cellular responders to proinflammatory molecules of acute inflammation in humans; PMNs of human milk are hypofunctional (72). Normal PMNs from blood are quenched by human milk: they exhibit reduced

adherence, spontaneous shape change, and deformability, their enzyme activity and release of reactive oxygen metabolites are suppressed, and microbial killing decreases (72). The function of milk cellular components in ontogeny of the mucosal immune system of the breast-fed infant remains a compelling area of research.

Large amounts and a number of complex carbohydrate structures, glycans, and especially oligosaccharides are unique to human milk and essentially indigestible by mammalian gut. That approximately 10% of the maternal caloric input for milk production would be expended synthesizing nonnutrient glycans seems counterintuitive, but indigestible dietary glycans often influence the composition of the intestinal microbiota. Most of these glycans arrive intact in the distal gut, where, as substrates for fermentation, they stimulate colonization by microbes that have a positive effect on the health of the mammalian host; that is, they are prebiotics (85). The importance of a fully colonized gut may be of increasing importance in societies where exposure to microflora is reduced by high, perhaps excessive, levels of hygiene (86,87). Increased colonization by bifidobacteria and lactobacillae in breast-fed infants may enhance subsequent long-term formation of a stable microbial ecosystem by favoring symbiotic (mutualist) anaerobes (88,89) and inhibiting colonization by enteric pathogens, protecting the infant from disease (85).

Specific human milk glycans inhibit binding by specific pathogens to their cell surface receptors on the intestinal epithelium (Fig. 2 A and B) based on structural homology between the milk glycan and the glycan moiety of the host cell receptor. In humans, many of these glycans are fucosylated and contain the Lewis histo-blood group antigens. The Lewis epitopes are expressed constitutively and vary in expression due to genetic variation in the population. A strong direct association exists between concentrations of these glycans in

milk and protection from specific pathogens in breast-fed infants, and this association can account for much of the protection by human milk against many human enteropathogens (90,91). Although specific glycans inhibit only specific pathogens, the large numbers of human milk glycans in aggregate seem to defend the infant from many bacterial, viral, fungal, and other pathogens. We define these glycans as the major contributors to the innate immune system of human milk whereby the mother protects her infant from a wide array of pathogens.

Expression of inhibitory glycans varies in milk according to the genotype of the mother (91), and expression of glycans in the intestinal mucosa of the infant varies by genotype of the infant. Glycan expression in milk and gut also vary developmentally (92,93). Gut expresses more sialylated glycans from birth to weaning (3 wk in rats and mice), shifting to a predominance of fucosylated glycans (94). The expression of sialylated glycans longitudinally in human milk is not known, but expression of different patterns of fucosylated glycans in human milk seems to undergo a transition at around 6 to 9 mo (92). The relationship between expression of fucosylated glycans in intestine, expression in milk, inhibition of specific pathogens, and regulation of colonization (95) may have significant clinical ramifications, especially in high-risk and premature infants.

SPECULATIONS

Expression of components of the innate immune system of human milk change over the course of lactation, while simultaneously the ontogeny of the infant gut, and of its mucosal




Figure 2. Protection of infant gut by human milk glycans. (A) In infants fed artificial formula or milk lacking protective glycans, pathogens such as the noroviruses bind to their glycan receptors on the mucosal surface, which is the essential first step in their pathogenesis. (B) For infants consuming human milk that contains glycans homologous to the infant gut receptors, when pathogens such as noroviruses enter the gut, they are bound to the soluble glycans of milk, rendering them less likely to bind to mucosal receptors, thereby protecting the infant. (Adapted from Newburg DS and Street JM 1997 *Nutr Today* 32:191–201, © 1997 Lippincott Williams & Wilkins, with permission).




Figure 3. Milk glycans and intestinal microbiota can protect synergistically. The intestinal mucosal surface glycans are targets of pathogens, but can also be used as receptors for mutualist microbiota that colonize the gut and form a biofilm. Human milk glycans promote this colonization through their probiotic activity. The human milk glycans also bind to the pathogens, rendering them less able to bind to their receptors on the mucosal cell surface. These processes would provide multiple layers of synergistic defense of the intestine of breast-feeding infants.

immune system, is unfolding. It is tempting to consider these as coordinated complementary events, but our understanding of both of these systems remains quite incomplete. Notwithstanding, we speculate that human milk could provide exogenous signals and components for the ontogeny of the gut. We further hypothesize that human milk components modulate inflammation induced by microbes, both pathogenic and mutualist symbionts, in the immature intestinal mucosa of infants. During early exposure to some pathogens, this could result in subclinical infections that allow the formation of immunologic memory to pathogens without the negative consequences of hyperimmune responses that otherwise could divert nutrients away from growth and development.

The ontogeny of a complex dynamic microflora may also be intimately linked to changes during ontogeny of the gut and may be influenced by changes in human milk components over the course of lactation. Microbiota differs between breast-fed infants and artificially fed infants of the same age, and in both, the microbiota changes over the course of maturation of the intestine. We have observed changes in glycosylation of the intestinal mucosa during early development, changes in expression of human milk glycans over the course of lactation, and changes in gut microflora coincident with these two. A synergistic relationship among the three is proposed in Figure 3.

SUMMARY

Compelling but incomplete evidence suggests interdependent links among human milk components, ontogeny of intestinal function, development of the mucosal immune system, colonization by intestinal microbiota, and protection against pathogens. Timely coordination of these interactions seems to optimize the health potential of neonates. However, the challenge remains to identify the specific components that coordinate these interactions. Our understanding is confounded by the spatial and temporal specificity for many of the active components of both milk and the intestine, which can have complementary, additive, or synergistic interactions (58). Normal regulation of these systems seems to minimize acute conditions such as diarrhea, otitis media, and respiratory disease, and chronic conditions such as inflammatory bowel disease, allergy, obesity, cancer, and other manifestations of autoimmune dysfunction. The complexity and potential for dysfunction is multiplied in the premature infant in whom the immaturity of these systems may underlie NEC and other inflammatory bowel diseases. Moreover, inappropriate inflammatory responses during early life can divert nutrients from their support of growth (86): The brain is developing rapidly during this period, and any decrement of growth can lead to long-term deficits in learning (96). Better understanding of these interactions should help improve the composition of formulas for premature and term infants and may provide further evidence supporting promotion of breast-feeding for all infants.

REFERENCES

- Insoft RM, Sanderson IR, Walker WA 1996 Development of immune function in the intestine and its role in neonatal diseases. *Pediatr Clin North Am* 43:551-571
- Newburg DS 2000 Oligosaccharides in human milk and bacterial colonization. *J Pediatr Gastroenterol Nutr* 30:S8-S17
- Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA 2005 Diversity of the human intestinal microbial flora. *Science* 308:1635-1638
- Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI 2001 Molecular analysis of commensal host-microbial relationships in the intestine. *Science* 291:881-884
- Russell MW, Kilian M 2004 Biological activities of Ig. In: Mestecky J, Lamm ME, McGhee JR, Bienenstock J, Mayer L, Strober W (eds) *Mucosal Immunology*. Academic Press, New York, pp 267-289
- Van Itallie CM, Anderson JM 2004 The molecular physiology of tight junction pores. *Physiology (Bethesda)* 19:331-338
- Gewirtz AT, Sitaraman SV, Merlin D, Madara JL 2003 Pathogen-initiated inflammatory response in intestinal epithelial cells: cross talk with neutrophils. In: Hecht GA (ed) *Microbial Pathogenesis and the Intestinal Epithelial Cell*. ASM Press, Washington, DC, pp 141-154
- Brandtzaeg P 2001 Development, regulation and function of secretory immunity. In: Delvin E, Lentze MJ (eds) *Gastrointestinal Functions*. Vevey/Lippincott Williams & Wilkins, Philadelphia, pp 91-114
- Henning SJ 1987 Functional development of the gastrointestinal tract. In: Johnson LR (ed) *Physiology of the Gastrointestinal Tract*. Raven Press, New York, pp 285-300
- Hamosh M 1990 Lingual and gastric lipases. *Nutrition* 6:421-428
- Thormar H, Isaacs CE, Brown HR, Barshatzky MR, Pessolano T 1987 Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. *Antimicrob Agents Chemother* 31:27-31
- Gork AS, Usui N, Ceriati E, Drongowski RA, Epstein MD, Coran AG, Harmon CM 1999 The effect of mucin on bacterial translocation in I-407 fetal and Caco-2 adult enterocyte cultured cell lines. *Pediatr Surg Int* 15:155-159
- Nanthakumar NN 2001 Regulation of functional development of the small intestine. In: Delvin E, Lentze MJ (eds) *Gastrointestinal Functions*. Vevey/Lippincott Williams & Wilkins, Philadelphia, pp 39-58
- Frey A, Giannasca KT, Weltzin R, Giannasca PJ, Reggio H, Lencer WI, Neutra MR 1996 Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. *J Exp Med* 184:1045-1059
- Leblond CP 1981 The life history of cells in renewing systems. *Am J Anat* 160:114-158
- Eckmann L 2004 Innate immunity and mucosal bacterial interactions in the intestine. *Curr Opin Gastroenterol* 20:82-88
- Bevins CL 2005 Events at the host-microbial interface of the gastrointestinal tract. V. Paneth cell alpha-defensins in intestinal host defense. *Am J Physiol Gastrointest Liver Physiol* 289:G173-G176
- Ouellette AJ 2005 Paneth cell alpha-defensins: peptide mediators of innate immunity in the small intestine. *Springer Semin Immunopathol* 27:133-146
- Nanthakumar NN, Dai D, Newburg DS, Walker AW 2003 The role of indigenous microflora in the development of murine intestinal fucosyl- and sialyltransferases. *FASEB J* 17:44-46
- Robbe C, Capon C, Coddeville B, Michalski JC 2004 Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. *Biochem J* 384:307-316
- Bjerknes M, Cheng H 2005 Gastrointestinal stem cells. II. Intestinal stem cells. *Am J Physiol Gastrointest Liver Physiol* 289:G381-G387
- Wong MH 2004 Regulation of intestinal stem cells. *J Invest Dermatol Symp Proc* 9:224-228
- Bry L, Falk P, Huttner K, Ouellette A, Midtvedt T, Gordon JI 1994 Paneth cell differentiation in the developing intestine of normal and transgenic mice. *Proc Natl Acad Sci U S A* 91:10335-10339
- Stappenbeck TS, Mills JC, Gordon JI 2003 Molecular features of adult mouse small intestinal epithelial progenitors. *Proc Natl Acad Sci U S A* 100:1004-1009
- Phadke SM, Deslouches B, Hileman SE, Montelaro RC, Wiesenfeld HC, Mietzner TA 2005 Antimicrobial peptides in mucosal secretions: the importance of local secretions in mitigating infection. *J Nutr* 135:1289-1293
- Neutra MR, Mantis NJ, Frey A, Giannasca PJ 1999 The composition and function of M cell apical membranes: implications for microbial pathogenesis. *Semin Immunol* 11:171-181
- Nagler-Anderson C 2001 Man the barrier! Strategic defences in the intestinal mucosa. *Nat Rev Immunol* 1:59-67
- Shi HN, Walker A 2004 Bacterial colonization and the development of intestinal defences. *Can J Gastroenterol* 18:493-500
- Rescigno M, Borro P 2001 The host-pathogen interaction: new themes from dendritic cell biology. *Cell* 106:267-270
- Cherayil BJ, Walker WA 2003 Ontogeny of the host response to enteric microbial infection. In: Hecht GA (ed) *Microbial Pathogenesis and the Intestinal Epithelial Cell*. ASM Press, Washington, DC, pp 333-349
- Dai D, Nanthakumar NN, Newburg DS, Walker WA 2000 Role of oligosaccharides and glycoconjugates in intestinal host defense. *J Pediatr Gastroenterol Nutr* 30:S23-S33
- Gurish MF, Boyce JA 2002 Mast cell growth, differentiation, and death. *Clin Rev Allergy Immunol* 22:107-118
- Furuta GT, Schmidt-Choudhury A, Wang MY, Wang ZS, Lu L, Furlano RI, Wershil BK 1997 Mast cell-dependent tumor necrosis factor alpha production participates in allergic gastric inflammation in mice. *Gastroenterology* 113:1560-1569

34. McGee DW 1999 Inflammation and mucosal cytokine production. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR (eds) *Mucosal Immunology*. Academic Press, San Diego, pp 559–573
35. Luster AD, Alon R, von Andrian UH 2005 Immune cell migration in inflammation: present and future therapeutic targets. *Nat Immunol* 6:1182–1190
36. Kawai T, Akira S 2006 Innate immune recognition of viral infection. *Nat Immunol* 7:131–137
37. Beutler B 2005 The Toll-like receptors: analysis by forward genetic methods. *Immunogenetics* 57:385–392
38. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr 1997 A human homologue of the *Drosophila* Toll protein signals activation of adaptive immunity. *Nature* 388:394–397.
39. Sanderson IR, Walker WA 2007 The role of TLRs/Nods in intestinal development and homeostasis. *Am J Physiol Gastrointest Liver Physiol*, in press
40. Tanabe H, Ayabe T, Bainbridge B, Guina T, Ernst RK, Darveau RP, Miller SI, Ouellette AJ 2005 Mouse Paneth cell secretory responses to cell surface glycolipids of virulent and attenuated pathogenic bacteria. *Infect Immun* 73:2312–2320
41. Nanthakumar NN, Fusunyan RD, Sanderson I, Walker WA 2000 Inflammation in the developing human intestine: a possible pathophysiologic contribution to necrotizing enterocolitis. *Proc Natl Acad Sci U S A* 97:6043–6048
42. Medvedev AE, Sabroe I, Hasday JD, Vogel SN 2006 Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. *J Endotoxin Res* 12:133–150
43. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M 2001 Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. *J Immunol* 167:1609–1616
44. Savidge TC, Newman PG, Pan WH, Weng MQ, Shi HN, McCormick BA, Quaroni A, Walker WA 2006 Lipopolysaccharide-induced human enterocyte tolerance to cytokine-mediated interleukin-8 production may occur independently of TLR-4/MD-2 signaling. *Pediatr Res* 59:89–95
45. Newburg DS 2001 Bioactive components of human milk: evolution, efficiency, and protection. *Adv Exp Med Biol* 501:3–10
46. Grulee CG, Sanford HN, Herron PH 1934 Breast and artificial feeding: Influence on morbidity and mortality of twenty thousand infants. *JAMA* 103:735–738
47. Brandtzaeg P 2003 Mucosal immunity: integration between mother and the breast-fed infant. *Vaccine* 21:3382–3388
48. Khadivzadeh T, Parsai S 2004 Effect of exclusive breastfeeding and complementary feeding on infant growth and morbidity. *East Mediterr Health J* 10:289–294
49. Morrow AL, Guerrero ML, Shults J, Calva JJ, Lutter C, Bravo J, Ruiz-Palacios G, Morrow RC, Butterfoss FD 1999 Efficacy of home-based peer counselling to promote exclusive breastfeeding: a randomised controlled trial. *Lancet* 353:1226–1231
50. Howie PW, Forsyth JS, Ogston SA, Clark A, Florey CD 1990 Protective effect of breast feeding against infection. *BMJ* 300:11–16
51. Quigley MA, Cumberland P, Cowden JM, Rodrigues LC 2006 How protective is breast feeding against diarrhoeal disease in infants in 1990s England? A case-control study. *Arch Dis Child* 91:245–250
52. Israel EJ 1994 Neonatal necrotizing enterocolitis, a disease of the immature intestinal mucosal barrier. *Acta Paediatr Suppl* 396:27–32
53. Kliegman RM, Walker WA, Yolken RH 1993 Necrotizing enterocolitis: research agenda for a disease of unknown etiology and pathogenesis. *Pediatr Res* 34:701–708
54. Hanson LA, Ceafalau L, Matsuy-Baltzer I, Lagerberg M, Hjalmarsson A, Ashraf R, Zaman S, Jalil F 2000 The mammary gland-infant intestine immunologic dyad. *Adv Exp Med Biol* 478:65–76
55. Boudry G, Peron V, Le Huerou-Luron I, Lalles JP, Seve B 2004 Weaning induces both transient and long-lasting modifications of absorptive, secretory, and barrier properties of piglet intestine. *J Nutr* 134:2256–2262
56. Teichberg S, Isolaure E, Wapnir RA, Roberts B, Lifshitz F 1990 Development of the neonatal rat small intestinal barrier to nonspecific macromolecular absorption: effect of early weaning to artificial diets. *Pediatr Res* 28:31–37
57. Udall JN, Colony P, Fritze L, Pang K, Trier JS, Walker WA 1981 Development of gastrointestinal mucosal barrier. II. The effect of natural versus artificial feeding on intestinal permeability to macromolecules. *Pediatr Res* 15:245–249
58. Newburg DS 2005 Innate immunity and human milk. *J Nutr* 135:1308–1312
59. Schlossman A, Moro E 1903 Zur Kenntniss der Arteinheit der verschiedenen Eiweisskörper der Milch. *Munch Med Wochschr* 1:597–602
60. Hanson L 1961 Comparative immunological studies of the immune globulins of human milk and blood serum. *Int Arch Allergy Appl Immunol* 18:241–267
61. Uren TK, Wijburg OL, Simmons C, Johansen FE, Brandtzaeg P, Strugnell RA 2005 Vaccine-induced protection against gastrointestinal bacterial infections in the absence of secretory antibodies. *Eur J Immunol* 35:180–188
62. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG 2003 Human lactoferrin impairs virulence of *Shigella flexneri*. *J Infect Dis* 187:87–95
63. Gomez HF, Ochoa TJ, Herrera-Insua I, Carlin LG, Cleary TG 2002 Lactoferrin protects rabbits from *Shigella flexneri*-induced inflammatory enteritis. *Infect Immun* 70:7050–7053
64. Ochoa TJ, Noguera-Obenza M, Ebel F, Guzman CA, Gomez HF, Cleary TG 2003 Lactoferrin impairs type III secretory system function in enteropathogenic *Escherichia coli*. *Infect Immun* 71:5149–5155
65. Lima MF, Kierszenbaum F 1987 Lactoferrin effects of phagocytic cell function. II. The presence of iron is required for the lactoferrin molecule to stimulate intracellular killing by macrophages but not to enhance the uptake of particles and microorganisms. *J Immunol* 139:1647–1651
66. Harmsen MC, Swart PJ, de Bethune M-P, Pauwels R, De Clercq E, The H, Mekjer DK 1995 Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. *J Infect Dis* 172:380–388
67. Hasegawa K, Motosuchi W, Tanaka S, Dosako S 1994 Inhibition with lactoferrin of in vitro infection with human herpes virus. *Jpn J Med Sci Biol* 47:73–85
68. Goldman AS, Garza C, Nichols BL, Goldblum RM 1982 Immunologic factors in human milk during the first year of lactation. *J Pediatr* 100:563–567
69. Hamosh M 1998 Protective function of proteins and lipids in human milk. *Biol Neonate* 74:163–176
70. Gustafsson L, Boiers C, Hallgren O, Mossberg A-K, Pettersson J, Fischer W, Aronsson A, Svanborg C 2005 HAMLET kills tumor cells by apoptosis: structure, cellular mechanisms, and therapy. *J Nutr* 135:1299–1303
71. Claud EC, Savidge T, Walker WA 2003 Modulation of human intestinal epithelial cell IL-8 secretion by human milk factors. *Pediatr Res* 53:419–425
72. Buescher ES 2001 Anti-inflammatory characteristics of human milk: how, where, why. *Adv Exp Med Biol* 501:207–222
73. Buescher ES, Malinowska I 1996 Soluble receptors and cytokine antagonists in human milk. *Pediatr Res* 40:839–844
74. Zucali JR, Broxmeyer HE, Levy D, Morse C 1989 Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1. *Blood* 74:1531–1536
75. Saito S, Maruyama M, Kato Y, Moriyama I, Ichijo M 1991 Detection of IL-6 in human milk and its involvement in IgA production. *J Reprod Immunol* 20:267–276
76. Saito S, Yoshida M, Ichijo M, Ishizaka S, Tsujii T 1993 Transforming growth factor-beta (TGF-beta) in human milk. *Clin Exp Immunol* 94:220–224
77. Bousvarous A, Walker WA 1990 The development of the intestinal mucosal barrier. In: MacDonald T (ed) *Ontogeny of the Immune Response of the Gut*. CRC Press, Boca Raton, FL, pp 1–21
78. LeBouder E, Rey-Nores JE, Raby AC, Affolter M, Vidal K, Thornton CA, Labeta MO 2006 Modulation of neonatal microbial recognition: TLR-mediated innate immune responses are specifically and differentially modulated by human milk. *J Immunol* 176:3742–3752
79. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA 1999 Phylogenetic perspectives in innate immunity. *Science* 284:1313–1318
80. Labeta MO, Vidal K, Nores JE, Arias M, Vita N, Morgan BP, Guillemot JC, Loyaux D, Ferrara P, Schmid D, Affolter M, Borysiewicz LK, Donnet-Hughes A, Schiffrin EJ 2000 Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. *J Exp Med* 191:1807–1812
81. Mykoniatis A, Anton PM, Wik M, Wang CC, Ungsuan L, Blusher S, Venihaki M, Simeonidis S, Zacks J, Zhao D, Sougioultzis S, Karalis K, Mantzoros C, Pothoulakis C 2003 Leptin mediates *Clostridium difficile* toxin A-induced enteritis in mice. *Gastroenterology* 124:683–691
82. Weaver LT, Gonnella PA, Israel EJ, Walker WA 1990 Uptake and transport of epidermal growth factor by the small intestinal epithelium of the fetal rat. *Gastroenterology* 98:828–837
83. Martin LJ, Woo JG, Geraghty SR, Altaye M, Davidson BS, Banach W, Dolan LM, Ruiz-Palacios GM, Morrow AL 2006 Adiponectin is present in human milk and is associated with maternal factors. *Am J Clin Nutr* 83:1106–1111
84. Hasselbalch H, Engelmann MD, Ersboll AK, Jeppesen G, Fleischer-Michaelsen K 1999 Breast-feeding influences thymic size in late infancy. *Eur J Pediatr* 158:964–967
85. Macfarlane GT, Macfarlane S 1997 Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. *Scand J Gastroenterol Suppl* 222:3–9
86. Bach JF 2002 The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med* 347:911–920
87. Wills-Karp M, Santeliz J, Karp CL 2001 The germless theory of allergic disease: revisiting the hygiene hypothesis. *Nat Rev Immunol* 1:69–75
88. Orrhage K, Nord CE 1999 Factors controlling the bacterial colonization of the intestine in breastfed infants. *Acta Paediatr Suppl* 88:47–57
89. Savage DC 1977 Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol* 31:107–133
90. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero ML, Meinen-Derr JK, Farkas T, Chaturvedi P, Pickering LK, Newburg DS 2004 Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. *J Pediatr* 145:297–303
91. Newburg DS, Ruiz-Palacios GM, Altaye M, Chaturvedi P, Meinen-Derr J, Guerrero ML, Morrow AL 2004 Innate protection conferred by fucosylated oligosaccharides of human milk against diarrhea in breastfed infants. *Glycobiology* 14:253–263
92. Chaturvedi P, Warren CD, Altaye M, Morrow AL, Ruiz-Palacios G, Pickering LK, Newburg DS 2001 Fucosylated human milk oligosaccharides vary between individuals and over the course of lactation. *Glycobiology* 11:365–372
93. Nanthakumar NN, Dai D, Meng D, Chaudry N, Newburg DS, Walker WA 2005 Regulation of intestinal ontogeny: effect of glucocorticoids and luminal microbes on galactosyltransferase and trehalase induction in mice. *Glycobiology* 15:221–232
94. Pang KY, Bresson JL, Walker WA 1987 Development of gastrointestinal surface. VIII. Lectin identification of carbohydrate differences. *Am J Physiol* 252:G685–G691
95. Smith PL, Myers JT, Rogers CE, Zhou L, Petryniak B, Becker DJ, Homeister JW, Lowe JB 2002 Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus. *J Cell Biol* 158:801–815
96. Newburg DS, Frankel DL, Fillios LC 1975 An asparagine requirement in young rats fed the dietary combinations of aspartic acid, glutamine, and glutamic acid. *J Nutr* 105:356–363